A regimen combining the Wee1 inhibitor AZD1775 with HDAC inhibitors targets human acute myeloid leukemia cells harboring various genetic mutations.
about
Update on rational targeted therapy in AMLTargeting cell cycle regulators in hematologic malignancies.Rational Combinations of Targeted Agents in AMLChromatin states modify network motifs contributing to cell-specific functions.Identification of Synergistic, Clinically Achievable, Combination Therapies for OsteosarcomaSynergistic anti-leukemic interactions between panobinostat and MK-1775 in acute myeloid leukemia ex vivo.The NAE inhibitor pevonedistat interacts with the HDAC inhibitor belinostat to target AML cells by disrupting the DDR.Cell cycle proteins as promising targets in cancer therapyRomidepsin for the treatment of non-Hodgkin's lymphoma.Emerging cell cycle inhibitors for acute myeloid leukemia.The cell cycle checkpoint inhibitors in the treatment of leukemias.WEE1 is a validated target of the microRNA miR-17-92 cluster in leukemia.Treatment of Relapsed/Refractory Acute Myeloid Leukemia.Positive transcription elongation factor b (P-TEFb) is a therapeutic target in human multiple myeloma.Suppression of Sirt1 sensitizes lung cancer cells to WEE1 inhibitor MK-1775-induced DNA damage and apoptosis.Replication Stress Leading to Apoptosis within the S-phase Contributes to Synergism between Vorinostat and AZD1775 in HNSCC Harboring High-Risk TP53 Mutation.Chemotherapy-induced differential cell cycle arrest in B cell lymphomas affects their sensitivity to Wee1 inhibition.Targeting WEE1 to enhance conventional therapies for acute lymphoblastic leukemia
P2860
Q26766152-B11A7E11-BFDB-44DC-A999-4739B9A79207Q35334436-412707FC-0F6D-4A5B-8A69-D4F45F3A58EAQ35750491-C2B8C192-7BA4-4B40-9357-E199CD60C95DQ35847789-2EC71C91-843D-4701-BA11-B2961A2ECC14Q36316518-C1B1527C-F73B-4216-BB4F-51A2A1FAC3B9Q36843733-675F5850-9802-4522-8E47-DA7D649A0CB3Q36876973-76FCAABA-5121-465E-AE38-9A373D81FDC9Q37693690-7DE660F0-02F9-4CF5-A99E-867C4B82AEBFQ38455740-9BAB58A7-7FAE-4E72-A3B6-15658AE66A2AQ38785380-8FF1F6DA-96E0-4F45-AC71-BEEC0A5BC425Q38868502-01F32205-AF90-4A01-BBED-CAC86B6654D6Q38904522-DA245C11-B606-41D9-97DE-BEB860F6DB83Q39175665-1AB80CDB-71E1-409C-BB98-DB27D6AAD9B9Q41708707-BF77CE3C-7951-4B7E-B83D-861D898A11F6Q47719669-99B6E6A4-07CE-497B-81E1-37E38FFBF48AQ48698494-A1EB6C4F-8E5D-4E96-A5E7-8F6E3D8992DDQ50020989-66019575-D674-4FDF-81F2-3DAAF9586284Q56355417-04DEDC99-C98D-4DC8-9AE1-B2AB97B382FE
P2860
A regimen combining the Wee1 inhibitor AZD1775 with HDAC inhibitors targets human acute myeloid leukemia cells harboring various genetic mutations.
description
2014 nî lūn-bûn
@nan
2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
name
A regimen combining the Wee1 i ...... ing various genetic mutations.
@ast
A regimen combining the Wee1 i ...... ing various genetic mutations.
@en
type
label
A regimen combining the Wee1 i ...... ing various genetic mutations.
@ast
A regimen combining the Wee1 i ...... ing various genetic mutations.
@en
prefLabel
A regimen combining the Wee1 i ...... ing various genetic mutations.
@ast
A regimen combining the Wee1 i ...... ing various genetic mutations.
@en
P2093
P2860
P356
P1433
P1476
A regimen combining the Wee1 i ...... ing various genetic mutations.
@en
P2093
A Ferreira-Gonzalez
M Kmieciak
P2860
P2888
P304
P356
10.1038/LEU.2014.296
P577
2014-10-06T00:00:00Z